These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 7686766)
1. Treatment of carcinoid syndrome with recombinant interferon alpha-2a. Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M] Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766 [TBL] [Abstract][Full Text] [Related]
2. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour. Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359 [TBL] [Abstract][Full Text] [Related]
3. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Janson ET; Oberg K Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765 [TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon]. Doberauer C; Niederle N; Kloke O; Kurschel E; Schmidt CG Onkologie; 1987 Dec; 10(6):340-4. PubMed ID: 2450326 [TBL] [Abstract][Full Text] [Related]
7. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Välimäki M; Järvinen H; Salmela P; Sane T; Sjöblom SM; Pelkonen R Cancer; 1991 Feb; 67(3):547-9. PubMed ID: 1702352 [TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic carcinoid tumour with recombinant interferon alfa. Joensuu H; Kumpulainen E; Gröhn P Eur J Cancer; 1992; 28A(10):1650-3. PubMed ID: 1382493 [TBL] [Abstract][Full Text] [Related]
9. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948 [TBL] [Abstract][Full Text] [Related]
10. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643 [TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548 [TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Veenhof CH; de Wit R; Taal BG; Dirix LY; Wagstaff J; Hensen A; Huldij AC; Bakker PJ Eur J Cancer; 1992; 28(1):75-8. PubMed ID: 1373635 [TBL] [Abstract][Full Text] [Related]
13. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. Moertel CG; Rubin J; Kvols LK J Clin Oncol; 1989 Jul; 7(7):865-8. PubMed ID: 2738623 [TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128 [TBL] [Abstract][Full Text] [Related]
15. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. Janson ET; Kauppinen HL; Oberg K Acta Oncol; 1993; 32(2):231-3. PubMed ID: 8323762 [TBL] [Abstract][Full Text] [Related]
17. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802 [TBL] [Abstract][Full Text] [Related]
18. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b]. Linkesch M; Kuzmits R; Geyer G Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566 [TBL] [Abstract][Full Text] [Related]
19. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy. Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018 [TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Doberauer C; Mengelkoch B; Kloke O; Wandl U; Niederle N Acta Oncol; 1991; 30(5):603-5. PubMed ID: 1892678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]